IDH2 and central nervous system cancer: IDH mutation status is stable, while additional molecular events, such as allelic loss of 1p/ 19q (LOH 1p/19q) or TP53- mutations, accumulate during the progression of low-grade glioma to secondary high-grade glioma [19].